Weight loss medications are not just about pounds; they can influence sexual health in complex ways that deserve sober consideration from patients and clinicians alike, since decisions about therapy touch an entire spectrum of physical function and quality of life.

Recent analyses highlight that GLP-1 based therapies touch the body’s hormonal and vascular systems in ways that bear directly on sexual function, sometimes with as yet unpredictable consequences.

In obese and overweight men, GLP-1 drugs increased total testosterone, optimized hormone levels and improved erectile function scores, according to a 2025 review published by the National Institutes of Health.

Other reviews have reported similar improvements in erectile function among users, and the trend appears robust across multiple studies despite methodological differences.

Additional reviews found the same improvement in erectile dysfunction. The consistency across studies strengthens the case that hormonal and vascular mechanisms respond to GLP-1 therapies and that these effects are not limited to a single cohort or health profile.

A nationally representative Kinsey Institute survey of GLP-1 users found that about 52 percent reported that the medication had impacted their sex lives, with a broad spectrum of effects from increased desire to reduced arousal.

Eighteen percent said their sexual desire increased, while sixteen percent said it decreased; sixteen percent noted improved sexual desire and fourteen percent said it did not change.

Dr. Peter Balazs, a hormone and weight-loss specialist, cautions that it is difficult to determine whether improved sexual function stems from the medication itself or simply from the weight loss that often accompanies therapy.

He noted, “Individuals with severe obesity often experience meaningful hormonal improvements, whereas those with long-standing diabetic neuropathy may have irreversible neurovascular damage”.

That contrast underscores that dysfunction can have multiple roots and psychosocial factors can limit pharmacotherapy. Critically, when dysfunction is driven primarily by psychosocial factors, pharmacotherapy alone is unlikely to succeed.

In Balazs’ own practice, he reported seeing “both ends,” although most of his patients have improved sex lives, reflecting a broad range of responses to treatment and to the life changes that accompany weight loss.

He has observed a range of responses depending on individual health status, disease duration and the emotional climate surrounding relationships.

Men under 30 were more likely to report decreased libido. Balazs attributed this to the drug’s effects on the central nervous system rather than underlying health conditions, suggesting that younger patients face a distinct neurobiological dynamic when starting GLP-1 therapy.

GLP-1s can directly contribute to improved sexual function by improving vascular endothelial function, thereby supporting better blood flow. This vascular benefit is meaningful for overall cardiovascular health and, in men, can improve erectile function, while in women it can increase pelvic blood flow and potentially enhance arousal.

Substantial weight loss reduces the function that converts testosterone to estrogen, which can help restore testosterone levels. That restoration can improve libido, energy and overall sexual function.

On the other hand, reduced sexual function while taking a GLP-1 drug could occur due to reward signaling in the brain.

A reward system that governs both eating and sexual pleasure may influence desire in some patients depending on how the drug interacts with neural pathways.

“The central reward pathway contributes to pleasure associated with both food and sexual activity,” he said. “Its modulation may reduce sexual desire in some patients.”